Repligen to Acquire BioLife Solutions for $1.5 Billion

Repligen Corporation (RGEN) entered a merger agreement on July 22, 2026, to acquire BioLife Solutions, Inc. (BLFS) in a deal valued at $1.5 billion.

Deal Structure:

BioLife stockholders will receive $11.25 per share in cash and 0.1442 shares of Repligen common stock, for a total value of $31 per share, representing a 6.2% premium over the stock’s last close.

The transaction consideration will consist of 64% Repligen common stock and 36% cash.

Company Profile:

BioLife is a provider of bioproduction tools and services for the cell and gene therapy and broader biopharmaceutical markets. The company develops products for biopreservation, cryogenic storage, thawing, and temperature-controlled transportation to support the collection, manufacturing, storage, and distribution of biologic materials.

Repligen is a life sciences company that develops and supplies bioprocessing technologies and systems used in the manufacturing of biological drugs. Its product portfolio includes filtration, chromatography, process analytics, fluid management, and protein-based solutions for biopharmaceutical companies and contract manufacturers.

Deal Details and Timeline:

Last month, Bloomberg reported that Biolife had attracted takeover interest from parties including Repligen. The stock was trading at $28.67 when the rumor circulated, and it wasn’t clear if Biolife planned to respond to the interest.

BioLife’s products are an important part of the cell therapy process and fit well with Repligen’s existing product portfolio. Its biopreservation media, including CryoStor, are used in 18 approved cell therapies and in most commercially sponsored cell therapy clinical trials in the U.S. By joining Repligen, BioLife will gain access to Repligen’s larger global sales network, especially in the Asia-Pacific region.

The transaction is expected to increase Repligen’s revenue growth, adjusted profit margins, and adjusted earnings per share (EPS). The company expects the deal to add at least $0.05 to adjusted EPS in the first year and at least $0.25 in the second year. Repligen also expects to achieve at least $20 million in cost synergies in the first year and at least $30 million in the second year.

The cash portion of the transaction will be paid using Repligen’s existing cash reserves.

The merger is expected to close in the fourth quarter of 2026.

BioLife was advised by Centerview Partners as its financial advisor and K&L Gates as its legal counsel. Repligen was advised by Perella Weinberg Partners and Goldman Sachs as its financial advisors, and Goodwin Procter as its legal counsel.

Repligen is paying 13.81 times the sales for BioLife.

Deal Metrics:

For a deeper understanding of this M&A transaction, kindly refer to the Deal Metrics page here:

Deal Metrics for the acquisition of BioLife Solutions, Inc. (BLFS) by Repligen Corporation (RGEN)

The Deal Metrics page for each merger or acquisition includes:

• A spread history chart of the merger from announcement to completion or failure.
• A timeline of events as the merger progresses through the HSR period, regulatory approvals, shareholder votes, etc.
• News and SEC filings.
• A history of deal updates.
• And much more.

Disclaimer: We recommend conducting your own research and due diligence before investing in any securities mentioned in this article. We do not guarantee the completeness or accuracy of the content or data provided in this article.

Editor’s Note: Baranjot Kaur contributed to this article